Skip to content

Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery

Efficacy of Single Level Versus Bilevel Serratus Anterior Plane Block With Dexmedetomidine During Breast Cancer Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05361837
Enrollment
172
Registered
2022-05-05
Start date
2022-05-10
Completion date
2026-11-25
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia

Brief summary

This study aims to compare single level serratus block versus bilevel serratus block with and without dexmedetomidine in cancer patients undergoing modified radical mastectomy for breast cancer regarding pain control and possible side effects.

Interventions

PROCEDURESingle level serratus anterior plane block

Serratus anterior plane block with local anesthetics at the third rib

PROCEDURESingle level serratus anterior plane block with dexmedetomidine

Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib

PROCEDUREBilevel serratus anterior plane block

Serratus anterior plane block with local anesthetics at the third and fifth rib

PROCEDUREBilevel serratus anterior plane block with dexmedetomidine

Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib

Sponsors

National Cancer Institute, Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* patients scheduled for modified radical mastectomy, * Age 18-65 years, * ASA I-II

Exclusion criteria

* patient refusal, * coagulation defects, * abnormal kidney or liver functions, * local infection at site of injection.

Design outcomes

Primary

MeasureTime frameDescription
First time to receive analgesiaFirst 24 hours postoperativelyfirst time to receive morphine analgesia in hours
Total analgesic requisiteFirst 24 hours postoperativelytotal amount of morphine consumption in the first 24 hours postoperatively in mg

Secondary

MeasureTime frameDescription
Pain scoresFirst 24 hours postoperativelypain scores will be assessed using Visual Analogue Scale on a sale from 0 to 10 with 0 meanung no pain and 10 meaning severe pain
Side effectsFirst 24 hours postoperativelynausea and vomiting and hematoma at site of injection
Perioperative heart rate valuesFirst 24 hoursheart rate values in the form of beat per minute in the perioperative period including preoperative, intraoperative and postoperative
Mean arterial blood pressureFirst 24 hoursMean arterial blood pressure values in the form mmHg in the perioperative period including preoperative, intraoperative and postoperative

Countries

Egypt

Contacts

CONTACTWalaa Y Elsabeeny, MD
walaa.elsabeeny@nci.cu.edu.eg201007798466
CONTACTNahla N Shehab, MD
nahla.shehab2@gmail.com01221682808
PRINCIPAL_INVESTIGATORWalaa Y Elsabeeny, MD

Assistant Professor of Anesthesia and Pain management

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026